Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy

Background: We aimed to explore whether the expression of serum miR-222-3p might contribute to early prediction of therapeutic response, clinical outcomes, and adverse events for HER2-positive breast cancer patients receiving neoadjuvant therapy (NAT). Methods: A total of 65 HER2-positive breast can...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Oncol
Auteurs principaux: Zhang, Shan, Wang, Yaohui, Wang, Yan, Peng, Jing, Yuan, Chenwei, Zhou, Liheng, Xu, Shuguang, Lin, Yanping, Du, Yueyao, Yang, Fan, Zhang, Jie, Dai, Huijuan, Yin, Wenjin, Lu, Jinsong
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2020
Sujets:
Oncology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212359/
https://ncbi.nlm.nih.gov/pubmed/32426280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00631
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires